Oasmia Pharmaceutical AB, of Uppsala, Sweden, said it issued 22.94 million shares at SEK7.19 each to a limited group of investors for gross proceeds of approximately SEK165 million (US$17.6 million). The net proceeds are intended to be used to strengthen the working capital and finance ongoing operations.